NASDAQ:EXAS - EXACT Sciences Stock Price, News & Analysis

+1.30 (+1.10 %)
(As of 08/21/2019 01:49 AM ET)
Today's Range
Now: $119.46
50-Day Range
MA: $116.82
52-Week Range
Now: $119.46
Volume895,188 shs
Average Volume1.75 million shs
Market Capitalization$15.47 billion
P/E RatioN/A
Dividend YieldN/A
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolNASDAQ:EXAS



Sales & Book Value

Annual Sales$454.46 million
Book Value$5.54 per share


Net Income$-175,150,000.00


Market Cap$15.47 billion
Next Earnings Date10/29/2019 (Estimated)

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) released its quarterly earnings results on Monday, July, 29th. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.26. The medical research company had revenue of $199.87 million for the quarter, compared to analysts' expectations of $182.18 million. EXACT Sciences had a negative net margin of 35.43% and a negative return on equity of 28.90%. The firm's revenue for the quarter was up 94.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.30) earnings per share. View EXACT Sciences' Earnings History.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for EXACT Sciences.

What guidance has EXACT Sciences issued on next quarter's earnings?

EXACT Sciences updated its FY 2019 earnings guidance on Monday, July, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $800-810 million, compared to the consensus revenue estimate of $747 million.

What price target have analysts set for EXAS?

12 brokers have issued 12 month price targets for EXACT Sciences' stock. Their forecasts range from $90.00 to $143.00. On average, they expect EXACT Sciences' stock price to reach $117.90 in the next year. This suggests that the stock has a possible downside of 1.3%. View Analyst Price Targets for EXACT Sciences.

What is the consensus analysts' recommendation for EXACT Sciences?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.

What are Wall Street analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:
  • 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (8/1/2019)
  • 2. Canaccord Genuity analysts commented, "We reiterate EXAS as a top pick for 2019 and we raise our PT to $125. Is EXAS still a start-up? We don’t often ascribe $15B companies as “start-ups,” but given its sub-5% penetration rate on just one product, management, vision, and momentum building in Madison (energized with the new opening of lab which expands its capacity by 133% to 7M tests/year), we believe EXAS is just getting started. Pfizer has been a “home run” so far – we expect momentum to accelerate. Management indicated that its three-year partnership with Pfizer has been a “home run” so far. Pfizer reps (particularly the OBGYN reps who were just trained in Jan ’19) aren’t fully ramped yet. Add to this that Pfizer’s Lyrica went off patent two weeks ago, there is good reason to think that the best days working with PFE have not been realized yet." (7/17/2019)

Has EXACT Sciences been receiving favorable news coverage?

Press coverage about EXAS stock has been trending positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. EXACT Sciences earned a news impact score of 2.5 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for EXACT Sciences.

Who are some of EXACT Sciences' key competitors?

What other stocks do shareholders of EXACT Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), Aduro BioTech (ADRO), NVIDIA (NVDA), Micron Technology (MU), Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alibaba Group (BABA), Paypal (PYPL) and Advanced Micro Devices (AMD).

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)
  • Mr. Graham P. Lidgard, Chief Science Officer (Age 70)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Mark Stenhouse, Pres of Cologuard (Age 52)

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.90%), Price T Rowe Associates Inc. MD (5.55%), Jennison Associates LLC (2.55%), Viking Global Investors LP (1.75%), Winslow Capital Management LLC (1.74%) and Primecap Management Co. CA (1.38%). Company insiders that own EXACT Sciences stock include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

Which institutional investors are selling EXACT Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Price T Rowe Associates Inc. MD, Viking Global Investors LP, William Blair Investment Management LLC, Eaton Vance Management, Baillie Gifford & Co., Green Valley Investors LLC and Wasatch Advisors Inc.. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Michael S Wyzga and Scott C Johnson. View Insider Buying and Selling for EXACT Sciences.

Which institutional investors are buying EXACT Sciences stock?

EXAS stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, First Trust Advisors LP, Nuveen Asset Management LLC, Sumitomo Mitsui Trust Holdings Inc., Vanguard Group Inc., Westfield Capital Management Co. LP, Renaissance Technologies LLC and Victory Capital Management Inc.. View Insider Buying and Selling for EXACT Sciences.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $119.46.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $15.47 billion and generates $454.46 million in revenue each year. The medical research company earns $-175,150,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. EXACT Sciences employs 1,977 workers across the globe.View Additional Information About EXACT Sciences.

What is EXACT Sciences' official website?

The official website for EXACT Sciences is

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815.

MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  772 (Vote Outperform)
Underperform Votes:  467 (Vote Underperform)
Total Votes:  1,239
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel